

Airway Management: Use of Succinylcholine or Rocuronium *Practice Considerations*

Introduction

Each healthcare facility and its staff determine the appropriate medications required to safely manage routine and unexpected patient anesthesia needs. There have been reports of healthcare organizations considering replacing succinylcholine, a malignant hyperthermia (MH) triggering agent, with rocuronium, a non-depolarizing muscle relaxant, or keeping succinylcholine for emergent use and removing dantrolene from the formulary. These organizations are often small ambulatory surgery centers, endoscopy clinics, or office settings where succinylcholine may be the only MH-triggering agent on formulary. If succinylcholine is no longer available in the facility, the need for dantrolene to manage an MH crisis no longer exists. When appropriate for the patient, the combination of rocuronium and sugammadex, a neuromuscular blockade reversal agent, may provide an alternative to use of succinylcholine for emergent airway management in adults by providing complete reversal of the neuromuscular blockade, limiting the need for prolonged ventilation.¹

Position Statement

With a focus on patient safety, anesthetizing locations have access to medications, as identified by anesthesia professionals, to address routine and emergency oxygenation, ventilation, and airway management. All clinicians and staff are aware of the location of emergency equipment, supplies and medications. The facility complies with applicable federal, state and local law and regulations, accreditation standards, and internal policies and procedures.


Practice Considerations

- Succinylcholine is a depolarizing neuromuscular blocking agent (NMBA) with a rapid onset and elimination for spontaneous recovery to manage a difficult or emergent airway when return to spontaneous ventilation is desired and prolonged ventilation may not be available.
- Rocuronium may be used for difficult or emergent airway management, requiring a period of time for recovery of neuromuscular function before neostigmine or other cholinesterase inhibitor reversal agents are effective.
- In December 2015, the U.S. Food and Drug Administration (FDA) approved sugammadex in U.S. markets for the rapid reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide. Sugammadex encapsulates rocuronium or vecuronium, rendering the bound NMBA inactive to be eliminated by the kidneys.
- The combination of rocuronium and sugammadex may be an alternative to succinylcholine for neuromuscular blockade for airway management in many patients.
- When appropriate, consideration of contraindications and available alternatives to medications occurs during the patient assessment, evaluation and the informed consent

process when the patient is made aware of the medications to be used and the risks, benefits, and implications of those medications before, during, and after the procedure.

- When neuromuscular blocking and reversal agents are administered, monitor neuromuscular response to assess depth of blockade and degree of recovery.²
- Figure 1 highlights considerations and decision points for facilities and clinicians when determining which NMBA to have available in the anesthetizing location.

Figure 1. Use of Succinylcholine Compared to Rocuronium



Succinylcholine

Over time, succinylcholine has been the drug of choice to manage difficult and emergent airway issues in settings where sedation or anesthesia services are provided.³ Succinylcholine is currently the only rapid onset, short-duration depolarizing NMBA that produces an intense, consistent block used for rapid intubation, emergency airway management, and treatment of airway obstruction.⁴⁻⁸ When non-pharmacologic techniques do not resolve a laryngospasm,

intravenous or intramuscular succinylcholine, when intravenous access is not available, may improve ventilation or facilitate intubation of the airway.⁹ When succinylcholine is administered, possible adverse reactions should be considered (e.g., myalgia; hyperkalemia; bradycardia and cardiac dysrhythmias; increased intraocular, intracranial, and intragastric pressure; pseudocholinesterase deficiency; MH crisis).¹⁰⁻¹² When NMBAs are administered, facility policy includes procedures for ventilation and/or patient transport.

Dantrolene Required for Malignant Hyperthermia Crisis

Succinylcholine and certain inhaled anesthetic agents (e.g., halothane, sevoflurane, desflurane, and isoflurane) are known malignant hyperthermia triggering agents.¹³⁻¹⁵ Approximately 55 percent of MH cases in the United States and Canada have included the administration of succinylcholine, either alone or in combination with volatile anesthetics.¹⁵⁻¹⁷ Therefore, a facility that stocks MH-triggering agents, including succinylcholine, even if only for emergency airway management, should have dantrolene available and an MH crisis protocol in place.^{14,18} Immediate treatment of an MH crisis, including the use of dantrolene, is essential for patient survival.^{14,19} There is no guarantee that, even with careful health history screening, all patients at risk of MH crisis will be identified.

Rocuronium / Succinylcholine Comparison

When considering the risks and benefits of using rocuronium or succinylcholine, clinicians weigh multiple factors that include airway management, ability to ventilate and oxygenate, anaphylaxis, unanticipated difficult airway, and possible need for assisted or mechanical ventilation.²⁰ A “can’t ventilate, can’t intubate” scenario may be prolonged when rocuronium is administered.^{21,22} A neuromuscular blockade antagonist and equipment for oxygenation, airway management, and mechanical ventilation, and are available when neuromuscular blocking agents are administered.²³

Rocuronium has been administered as an alternative non-depolarizing NMBA for rapid airway management, including airway obstruction for adults and pediatric populations, and when succinylcholine is contraindicated.^{4,11,20,24-27} Rocuronium has a similar onset of action as succinylcholine with a dose of 1.0-1.2 mg/kg IV, but a longer, dose-dependent duration of action.^{12,28} Rocuronium may be used as an alternative to succinylcholine when succinylcholine is contraindicated, a similar rapid onset is desired, and a longer period of recovery from neuromuscular blockade is appropriate.^{25,29} If rocuronium is used in place of succinylcholine, for intubation at doses of 1.0-1.2 mg/kg IV, airway management supplies and equipment should be available to secure the airway and provide prolonged ventilation support until the neuromuscular blockade has been resolved.³⁰⁻³²

Sugammadex

Sugammadex has been shown to be safe and effective for reversal of neuromuscular blockade induced by rocuronium and vecuronium in three minutes or less.^{21,33-38} Reversal occurs at 1.5 min with a dose of 16 mg/kg and 3 min with a dose of 4 mg/kg. The availability of sugammadex provides anesthesia professionals an alternative for rocuronium-induced neuromuscular blockade reversal, minimizing or eliminating the need for succinylcholine for rapid airway management, intubation and treatment of airway obstruction.^{21,29,39} The rocuronium –

sugammadex combination may also optimize surgical conditions by allowing anesthesia professionals to maintain deep neuromuscular blockade throughout the procedure until the end of the case.²⁹ The assessment of neuromuscular recovery using a neuromuscular blockade monitor is recommended prior to extubation.⁵

In studies, sugammadex has been shown to provide a more rapid reversal of moderate rocuronium-induced neuromuscular blockade than neostigmine.^{40,41} Reversal using sugammadex for a high-dose rocuronium-induced neuromuscular block has been shown to take less time than spontaneous recovery from succinylcholine.^{42,43} Similar recovery times have been noted in pediatric and adult populations from sugammadex reversal of rocuronium-induced blockade.⁴⁴ Sugammadex doses vary based on patient age and comorbidities, the neuromuscular blocking agent used, and the depth of the neuromuscular block at the time of reversal.^{21,38} Results from a recent meta-analysis suggest that sugammadex is superior to neostigmine, as it reverses NMB faster and more reliably, with a lower risk of adverse effects.⁴⁵

When considering a combination of rocuronium and sugammadex for a difficult or emergent airway, conduct a risk-benefit analysis of time to prepare the sugammadex with the return of spontaneous respiration. Also, calculate the full reversal dose to have the drug dose and supplies necessary to prepare the drug available in the anesthetizing location.^{39,46}

Contraception Precaution

Since the efficacy of hormonal contraceptives may be reduced, patients using hormonal contraceptives should be advised to use an additional, non-hormonal contraceptive for seven days following sugammadex administration.¹ See package insert for full details on drug contraindications.¹

Conclusion

The ability of sugammadex to reverse rocuronium-induced NMB within 1.5 - 3.0 minutes of administration of a patient-specific dose is a rationale being considered for removal of succinylcholine and dantrolene, where no other MH triggering agents are present, from the formulary. Facilities and clinicians have an opportunity to work together when developing the drug formulary, as well as policy for medications, supplies, equipment, and skills necessary for patient safety regardless of facility type or location. Although studies have shown that there is no statistical difference in intubating conditions when succinylcholine was compared to rocuronium, succinylcholine provides the desirable clinical conditions due to its shorter duration of action.^{25,47} If rocuronium is available for airway management in place of succinylcholine, ventilation support or sugammadex should be available as a rapid reversal agent.^{48,49}

References

1. BRIDION® (sugammadex) Injection Prescribing Information. http://www.merck.com/product/usa/pi_circulars/b/bridion/bridion_pi.pdf. Accessed March 10, 2016.
2. Standards for Nurse Anesthesia Practice. Park Ridge, IL: American Association of Nurse Anesthetists; 2013.
3. Visvanathan T, Kluger MT, Webb RK, Westhorpe RN. Crisis management during anaesthesia: laryngospasm. *Qual Saf Health Care*. Jun 2005;14(3):e3.

4. Brown CA, 3rd, Bair AE, Pallin DJ, Walls RM, NEAR III Investigators. Techniques, success, and adverse events of emergency department adult intubations. *Ann Emerg Med.* Apr 2015;65(4):363-370.
5. Hampson-Evans D, Morgan P, Farrar M. Pediatric laryngospasm. *Paediatr Anaesth.* Apr 2008;18(4):303-307.
6. Mallon WK, Keim SM, Shoenberger JM, Walls RM. Rocuronium vs. succinylcholine in the emergency department: a critical appraisal. *J Emerg Med.* Aug 2009;37(2):183-188.
7. Alalami AA, Ayoub CM, Baraka AS. Laryngospasm: review of different prevention and treatment modalities. *Paediatr Anaesth.* Apr 2008;18(4):281-288.
8. Seupaul RA, Jones JH. Evidence-based emergency medicine. Does succinylcholine maximize intubating conditions better than rocuronium for rapid sequence intubation? *Ann Emerg Med.* Mar 2011;57(3):301-302.
9. Ruspantine P. Anesthesia Alert: Should You Stock Succinylcholine or Rocuronium? *Outpatient Surgery.* 2015; <http://www.outpatientsurgery.net/surgical-services/general-anesthesia/anesthesia-alert-should-you-stock-succinylcholine-or-rocuronium--07-15>. Accessed August 3, 2016.
10. Anectine: Package Insert and Label Information. <http://druginserts.com/lib/rx/meds/anectine/>. Accessed March 10, 2016.
11. McCourt KC, Salmela L, Mirakhor RK, et al. Comparison of rocuronium and suxamethonium for use during rapid sequence induction of anaesthesia. *Anaesthesia.* Sep 1998;53(9):867-871.
12. Frakes MA. Muscle relaxant choices for rapid sequence induction. *Air Med J.* Jan-Feb 2001;20(1):20-21.
13. Visoiu M, Young MC, Wieland K, Brandom BW. Anesthetic drugs and onset of malignant hyperthermia. *Anesth Analg.* Feb 2014;118(2):388-396.
14. Malignant Hyperthermia Crisis Preparedness and Treatment. Park Ridge, IL: American Association of Nurse Anesthetists; 2015.
15. Dexter F, Epstein RH, Wachtel RE, Rosenberg H. Estimate of the relative risk of succinylcholine for triggering malignant hyperthermia. *Anesth Analg.* Jan 2013;116(1):118-122.
16. Riazi S, Larach MG, Hu C, Wijeyesundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. *Anesth Analg.* Feb 2014;118(2):381-387.
17. Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. *Anesth Analg.* Feb 1 2010;110(2):498-507.
18. Malignant Hyperthermia Association of the United States. FAQs: Stocking an MH Cart. <http://www.mhaus.org/faqs/stocking-an-mh-cart>. Accessed February 29, 2016.
19. Malignant Hyperthermia Association of the United States. FAQs: Dantrolene. <http://www.mhaus.org/faqs/dantrolene>. Accessed April 13, 2016.
20. Cheng CA, Aun CS, Gin T. Comparison of rocuronium and suxamethonium for rapid tracheal intubation in children. *Paediatr Anaesth.* Feb 2002;12(2):140-145.
21. Schaller SJ, Fink H. Sugammadex as a reversal agent for neuromuscular block: an evidence-based review. *Core Evid.* 2013;8:57-67.

22. Welliver M, McDonough J, Kalynych N, Redfern R. Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent. *Drug Des Devel Ther.* 2009;2:49-59.
23. Rocuronium Bromide: Package Insert and Label Information. <http://druginserts.com/lib/rx/meds/rocuronium-bromide/>. Accessed March 2, 2016.
24. Gesek DJ, Jr. Respiratory anesthetic emergencies in oral and maxillofacial surgery. *Oral Maxillofac Surg Clin North Am.* Aug 2013;25(3):479-486, vii.
25. Tran DT, Newton EK, Mount VA, Lee JS, Wells GA, Perry JJ. Rocuronium versus succinylcholine for rapid sequence induction intubation. *Cochrane Database Syst Rev.* 2015;10:CD002788.
26. Patanwala AE, Stahle SA, Sakles JC, Erstad BL. Comparison of succinylcholine and rocuronium for first-attempt intubation success in the emergency department. *Acad Emerg Med.* Jan 2011;18(1):10-14.
27. Laurin EG, Sakles JC, Panacek EA, Rantapaa AA, Redd J. A comparison of succinylcholine and rocuronium for rapid-sequence intubation of emergency department patients. *Acad Emerg Med.* Dec 2000;7(12):1362-1369.
28. Sorensen MK, Bretlau C, Gatke MR, Sorensen AM, Rasmussen LS. Rapid sequence induction and intubation with rocuronium-sugammadex compared with succinylcholine: a randomized trial. *Br J Anaesth.* Apr 2012;108(4):682-689.
29. Soto R, Jahr JS, Pavlin J, et al. Safety and Efficacy of Rocuronium With Sugammadex Reversal Versus Succinylcholine in Outpatient Surgery-A Multicenter, Randomized, Safety Assessor-Blinded Trial. *Am J Ther.* Mar 12 2015.
30. Johnson EG, Meier A, Shirakbari A, Weant K, Baker Justice S. Impact of Rocuronium and Succinylcholine on Sedation Initiation After Rapid Sequence Intubation. *J Emerg Med.* Jul 2015;49(1):43-49.
31. Korinek JD, Thomas RM, Goddard LA, St John AE, Sakles JC, Patanwala AE. Comparison of rocuronium and succinylcholine on postintubation sedative and analgesic dosing in the emergency department. *Eur J Emerg Med.* Jun 2014;21(3):206-211.
32. Watt JM, Amini A, Traylor BR, Amini R, Sakles JC, Patanwala AE. Effect of paralytic type on time to post-intubation sedative use in the emergency department. *Emerg Med J.* Nov 2013;30(11):893-895.
33. Puhlinger FK, Rex C, Sielenkamper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. *Anesthesiology.* Aug 2008;109(2):188-197.
34. Yang LP, Keam SJ. Sugammadex: a review of its use in anaesthetic practice. *Drugs.* 2009;69(7):919-942.
35. Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. *Br J Anaesth.* Jan 2006;96(1):36-43.
36. Dahl V, Pendeville PE, Hollmann MW, Heier T, Abels EA, Blobner M. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. *Eur J Anaesthesiol.* Oct 2009;26(10):874-884.

37. de Boer HD, Driessen JJ, Marcus MA, Kerckamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. *Anesthesiology*. Aug 2007;107(2):239-244.
38. Partownavid P, Romito BT, Ching W, et al. Sugammadex: A Comprehensive Review of the Published Human Science, Including Renal Studies. *Am J Ther*. Jul-Aug 2015;22(4):298-317.
39. Chambers D, Paulden M, Paton F, et al. Sugammadex for reversal of neuromuscular block after rapid sequence intubation: a systematic review and economic assessment. *Br J Anaesth*. Nov 2010;105(5):568-575.
40. Blobner M, Eriksson LI, Scholz J, Motsch J, Della Rocca G, Prins ME. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. *Eur J Anaesthesiol*. Oct 2010;27(10):874-881.
41. Woo T, Kim KS, Shim YH, et al. Sugammadex versus neostigmine reversal of moderate rocuronium-induced neuromuscular blockade in Korean patients. *Korean J Anesthesiol*. Dec 2013;65(6):501-507.
42. Lee C, Jahr JS, Candiotti KA, Warriner B, Zornow MH, Naguib M. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. *Anesthesiology*. May 2009;110(5):1020-1025.
43. Rex C, Bergner UA, Puhlinger FK. Sugammadex: a selective relaxant-binding agent providing rapid reversal. *Curr Opin Anaesthesiol*. Aug 2010;23(4):461-465.
44. Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. *Anesthesiology*. Feb 2009;110(2):284-294.
45. Carron M, Zarantonello F, Tellaroli P, Ori C. Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. *J Clin Anesth*. 2016;35:1-12.
46. Martin C, Austin S, Latif U. Difficult mask ventilation and the use of sugammadex. *Anaesthesia*. May 2012;67(5):544-545.
47. Sluga M, Ummenhofer W, Studer W, Siegemund M, Marsch SC. Rocuronium versus succinylcholine for rapid sequence induction of anesthesia and endotracheal intubation: a prospective, randomized trial in emergent cases. *Anesth Analg*. Nov 2005;101(5):1356-1361.
48. Desforges JC, McDonnell NJ. Sugammadex in the management of a failed intubation in a morbidly obese patient. *Anaesth Intensive Care*. Jul 2011;39(4):763-764.
49. Bisschops MM, Holleman C, Huitink JM. Can sugammadex save a patient in a simulated 'cannot intubate, cannot ventilate' situation? *Anaesthesia*. Sep 2010;65(9):936-941.

Adopted by AANA Board of Directors September 2016.

© Copyright 2016

7 of 7

This document is not intended to provide a comprehensive discussion of each drug. Refer to each drug's package insert for indications of use, contraindications, dosage, adverse reactions, etc.